ClinicalTrials.gg
CompletedNCT05516966Updated Nov 15, 2024

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus

A Phase 1 interventional study of HRS9531 and Placebo in Diabetes Mellitus, Type 2, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-15.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ribupatide in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, 1 of them phase 3. ribupatide · Diabetes Mellitus, Type 2.

Enrollment
7th of 11
64 · median 72
Started
2022
the only one that year
Phase 1
7 of 11
none open now
Registered
2nd of 11
by date
Lead sponsor
11 of 11
Fujian Shengdi Pharmaceutical Co., Ltd.

Among the 11 studies testing ribupatide in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 1, and was the 2nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 11 studies testing ribupatide in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About ribupatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing ribupatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the safety and tolerability of multiple subcutaneous injections of HRS9531 in patients with type 2 diabetes mellitus who have suboptimal glycaemic control after conventional lifestyle or metformin intervention.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and infertility females, 18-65 years of age, inclusive, on the date of signing .
  2. Diagnosed with type 2 diabetes mellitus (T2DM) for at least 6 months.
  3. Treated with conventional lifestyle intervention alone or stable treatment with metformin (≥1000 mg/day) at least 8 weeks prior to screening.
  4. 7.0% ≤ ≤10.5% at screening.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of vital organ primary diseases, including but not limited to neuropsychiatric, cardiovascular, digestive, respiratory, urinary, endocrine, blood, immune and other diseases, judged by researchers to be unsuitable for this study.
  2. Diagnosed or suspected with type 1 diabetes mellitus, special types of diabetes or secondary diabetes.
  3. Have a history of acute complications of diabetes (diabetic ketoacidosis, lactic acidosis, hyperglycaemic hyperosmolar state, etc.) or episode of severe hypoglycaemic events within 12 months prior to screening.
  4. Have a presence of proliferative diabetic retinopathy, diabetic macular edema, or nonproliferative diabetic retinopathy requiring treatment during the trial;
  5. Participants in clinical trials of any drug or medical device in the 3 months prior to screening.
  6. Breast-feeding women.
  7. The investigator considers that the subject has any other factors that would make it inappropriate to participate in this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Group A

    Participants receive low dose level of HRS9531 or matched placebo administrated by multiple subcutaneous injection

    Drug: HRS9531 · Drug: Placebo

  • Experimental
    Group B

    Participants receive medium dose level of HRS9531 or matched placebo administrated by multiple subcutaneous injection

    Drug: HRS9531 · Drug: Placebo

  • Experimental
    Group C

    Participants receive high dose level of HRS9531 or matched placebo administrated by multiple subcutaneous injection

    Drug: HRS9531 · Drug: Placebo

  • Active comparator
    Group D

    Participants receive Dulaglutide 1.5 mg by multiple subcutaneous injection

    Drug: Dulaglutide Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (Safety and Tolerability)

    A summary of adverse events, including serious adverse events (SAEs) and Hypoglycemic Events

    Time frame: Screening period up to Day 62

Secondary outcomes

  1. Area Under the Concentration Versus Time Curve (AUC) of HRS9531

    Time frame: Start of Treatment up to Day 62

  2. Maximum Concentration (Cmax) of HRS9531

    Time frame: Start of Treatment up to Day 62

  3. Change from Baseline in Fasting Blood Glucose (FBG)

    Time frame: Baseline up to Day 62

  4. Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline up to Day 29

  5. Change from Baseline in Weight

    Time frame: Baseline up to Day 62

  6. Immunogenicity: anti-HRS9531 antibody

    Time frame: Start of Treatment up to Day 62

07

Study locations

1 site
  • Zhongshan Hospital Affiliated to Fudan University
    Shanghai, Shanghai 200000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in May 2023, 7 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 7 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2022
First posted
Aug 26, 2022
StartActual
Oct 12, 2022
Primary completionActual
May 24, 2023
CompletionActual
May 24, 2023
Last update
Nov 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05516966
Responsible party
Sponsor
First posted
Aug 26, 2022
Start date
Oct 12, 2022
Primary completion
May 24, 2023
Completion
May 24, 2023
Last update
Nov 15, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribupatide

Start the discussion